June 4, 2025

MMRF at ASCO 2025: Day 2 – What Patients Should Know

Welcome back to our coverage of the 2025 ASCO Annual Meeting. On Day 2, researchers shared more promising updates about long-term results from large, ongoing clinical trials, new treatment combinations, and patient-friendly innovations in multiple myeloma care. CAR T-Cell Therapy: Patients Cancer-Free After 5 Years Long-term data were presented from the CARTITUDE-1 study of the CAR-T […]

June 3, 2025

MMRF at ASCO 2025: Day 1 – What Patients Should Know

We’re excited to share highlights from the first day of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the year’s most important events in cancer research. This year, researchers from around the globe shared data on breakthrough research and treatment strategies, including 150 abstracts, posters, and presentations related to multiple myeloma. […]

June 3, 2025

Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma

New England Journal of Medicine, Ahead of Print.

June 3, 2025

Potential New Standard of Care Emerges in Multiple Myeloma – The ASCO Post

May 29, 2025

New Standard-of-Care Emerges for Multiple Myeloma – University of Miami